Evidence map›Paper›PMID 26433556›Full record

ReviewSeminars in oncology2015

Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.

Lori M Minasian, Catherine M Tangen, D Lawrence Wickerham

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lori M MinasianDivision of Cancer Prevention, U.S. National Cancer Institute, Rockville, MD. Electronic address: minasilo@mail.nih.gov.
Catherine M TangenPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
D Lawrence WickerhamDepartment of Human Oncology, Pittsburgh Campus of Temple University School of Medicine, Pittsburgh, PA.

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
SWOG Foreign AccrualsU10CA037429 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BLANKE, CHARLES D., MEYSKENS, FRANK L. · 1985 to 2014
$205.2M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Elaina Harper · 2014 to 2026
$146.4M
NRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5M
NSABP Foreign AccrualsU10CA037377 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WOLMARK, NORMAN · 1985 to 2014
$116.5M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
STUDY TO ASSESS RALOXIFENE FOR PREVENTING BREAST CANCERU10CA069974 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI COSTANTINO, JOSEPH P. · 1995 to 2013
$62.4M
GYNECOLOGIC ONCOLOGY GROUPU10CA101165 · NCI · GYNECOLOGIC ONCOLOGY GROUP · PI DISAIA, PHILIP J. · 2003 to 2014
$43.1M
NRG Oncology Biospecimen BankU24CA196067 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Tanner J. Freeman, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$42.6M
WHEAT BRAN FIBER SUPPLEMENTS ON THE RECURRENCE OF COLONIC ADENOMASP01CA041108 · NCI · UNIVERSITY OF ARIZONA · PI EINSPAHR, JANINE G · 1986 to 2009
$38.8M
SUPPLEMENTU10CA037404 · NCI · MAYO CLINIC ROCHESTER · PI LOPRINZI, CHARLES L · 1985 to 2014
$34.8M
Foreign Accrual - ECOGU10CA037403 · NCI · UNIVERSITY OF WISCONSIN MADISON · PI COMIS, ROBERT L · 1985 to 2014
$34.6M
NCI NIH HHS CA041108NCI NIH HHS CA101165NCI NIH HHS CA37377NCI NIH HHS CA37400NCI NIH HHS CA37403NCI NIH HHS CA37404NCI NIH HHS CA37420NCI NIH HHS CA37422NCI NIH HHS CA37429NCI NIH HHS CA37447NCI NIH HHS CA45809NCI NIH HHS CA69974NCI NIH HHS CA81851NCI NIH HHS CA81920NCI NIH HHS P01 CA041108NCI NIH HHS U10 CA037377NCI NIH HHS U10 CA037379NCI NIH HHS U10 CA037403NCI NIH HHS U10 CA037404NCI NIH HHS U10 CA037420NCI NIH HHS U10 CA037422NCI NIH HHS U10 CA037429NCI NIH HHS U10 CA037447NCI NIH HHS U10 CA045809NCI NIH HHS U10 CA069974NCI NIH HHS U10 CA081851NCI NIH HHS U10 CA081920NCI NIH HHS U10 CA101165NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS U24 CA196067NCI NIH HHS UG1 CA189867NCI NIH HHS UG1 CA189974NCI NIH HHS UM1 CA182883NCI NIH HHS UM1CA182883NEI NIH HHS EY014418NEI NIH HHS R01 EY014418NHLBI NIH HHS HL071722NIA NIH HHS AG019241NIA NIH HHS N01-AG-2106NIA NIH HHS R01 AG019241
6 · The paper itself

Abstract

Large cancer prevention trials provide opportunities to collect a wide array of data and biospecimens at study entry and longitudinally, for a healthy, aging population without cancer. This provides an opportunity to use pre-diagnostic data and specimens to evaluate hypotheses about the initial development of cancer. We report on strides made by, and future possibilities for, the use of accessible biorepositories developed from precisely annotated samples obtained through large-scale National Cancer Institute (NCI)-sponsored cancer prevention clinical trials conducted by the NCI Cooperative Groups. These large cancer prevention studies, which have enrolled more than 80,000 volunteers, continue to contribute to our understanding of cancer development more than 10 years after they were closed.

Indexed as

Biomedical ResearchClinical Trials as TopicCooperative BehaviorBiological Specimen BanksDatabases, FactualData CollectionHumansNational Cancer Institute (U.S.)NeoplasmsSpecimen HandlingUnited States

Identifiers

PMID26433556
PMCPMC4593316

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.